Viking Therapeutics Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 46-1073877(I.R.S. EmployerIdentification Number) Delaware(State or other jurisdiction ofincorporation or organization) 92121(Zip Code) (858) 704-4660(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: ClassNumber of Shares Outstandingas of April 15, 2026Common stock, $0.00001 par value116,105,643 VIKING THERAPEUTICS, INC.FORM 10-Q FOR THE THREE MONTHS ENDED MARCH 31, 2026TABLE OF CONTENTS Part I.FINANCIAL INFORMATION1Item 1.Condensed Consolidated Financial Statements1Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March31, 2026 and 2025 (unaudited)2Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and2025 (unaudited)3Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025(unaudited)4Notes to Condensed Consolidated Financial Statements (unaudited)5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures27Part II.OTHER INFORMATION28Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds66Item 3.Defaults Upon Senior Securities66Item 4.Mine Safety Disclosures66Item 5.Other Information67Item 6.Exhibits68SIGNATURES69 Viking Therapeutics, Inc.Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) Viking Therapeutics, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts)(Unaudited) Viking Therapeutics, Inc.Condensed Consolidated Statements of Stockholders’ Equity (In thousands, except share amounts)(Unaudited) Viking Therapeutics, Inc.Condensed Consolidated Statements of Cash Flows (In thousands)(Unaudited) Viking Therapeutics, Inc.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Organization and Summary of Significant Accounting Policies The Company VikingTherapeutics,Inc.,a Delaware corporation,together with its subsidiaries(the“Company”),is a clinical-stagebiopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. In June 2021,the Company formed an Australian subsidiary, Viking Therapeutics, PTY LTD, so as to be able to take advantage of certainresearch and development reimbursements available to local Australian-based research and development companies that choose todo research in Australia. In January 2025, the Company formed an Irish subsidiary, Viking Therapeutics Ireland Limited. The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive officesare located in San Diego, California, with a subsidiary located in Adelaide, Australia and a subsidiary located in Dublin, Ireland. Basis of Presentation The accompa